Recombinant human CCNL1 protein; Source: E. coli derived, PGEX-4T; Tag: GST; Domain: 227-526 aa of BC007081
Conjugate
Unconjugated
Applications
Application Notes
WB: 1:500-1:1000
General Notes
This product (Catalog No. DPABH-15367) is a rabbit-derived polyclonal antibody raised against human CCNL1, targeting the amino acid region 227–526 of the protein. This antibody exhibits cross-reactivity with Human CCNL1 from mouse and rat. It has been affinity purified by Protein A. CCNL1, also named as Cyclin-L1, contains a RS region and belongs to the cyclin family. CCNL1 localizes in the nucleus speckle and is Overexpressed in primary tumors of head and neck squamous cell carcinomas (HNSCC). CCNL1 as transcriptional regulator participates in regulating the pre-mRNA splicing process. It is seems to be involved in the regulation of RNA polymerase II (pol II). CCNL1 functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. It may be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). The calculated molecular weight of CCNL1 is about 55-60 kDa, but we detected a 40-50 kDa isoform by western blotting. DPABH-15367 is suitable for use in Western blot (WB) (1:500–1:1,000) application. DPABH-15367 is supplied as a liquid formulation in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
My Review for Rabbit Anti-Human CCNL1 (a.a. 227-526) Polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.